Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading Volume – Should You Buy?

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) saw unusually-high trading volume on Monday . Approximately 161,257 shares changed hands during mid-day trading, an increase of 114% from the previous session’s volume of 75,309 shares.The stock last traded at $36.0560 and had previously closed at $35.26.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. JMP Securities initiated coverage on Assembly Biosciences in a research note on Wednesday, September 24th. They issued a “market outperform” rating and a $38.00 price target on the stock. Citigroup began coverage on shares of Assembly Biosciences in a research note on Wednesday, September 24th. They issued an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research note on Monday. Finally, Mizuho set a $40.00 target price on Assembly Biosciences and gave the company an “outperform” rating in a report on Thursday, November 20th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Assembly Biosciences Stock Up 3.1%

The firm has a market cap of $574.90 million, a P/E ratio of -7.59 and a beta of 1.14. The business has a fifty day simple moving average of $33.27 and a 200-day simple moving average of $25.46.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%.The business had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $7.46 million. On average, sell-side analysts anticipate that Assembly Biosciences, Inc. will post -6.87 EPS for the current fiscal year.

Institutional Trading of Assembly Biosciences

A number of hedge funds have recently made changes to their positions in ASMB. American Century Companies Inc. purchased a new stake in shares of Assembly Biosciences in the first quarter worth $113,000. Acadian Asset Management LLC raised its holdings in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares during the last quarter. Palumbo Wealth Management LLC lifted its stake in shares of Assembly Biosciences by 3.8% in the second quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock worth $338,000 after buying an additional 681 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Assembly Biosciences by 6.9% during the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 3,312 shares during the last quarter. Finally, Ellsworth Advisors LLC purchased a new stake in shares of Assembly Biosciences during the third quarter valued at approximately $852,000. 19.92% of the stock is owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.